<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03766269</url>
  </required_header>
  <id_info>
    <org_study_id>140635</org_study_id>
    <nct_id>NCT03766269</nct_id>
  </id_info>
  <brief_title>Dronabinol Opioid Sparing Evaluation (DOSE) Trial</brief_title>
  <official_title>Dose-Titration Study to Evaluate the Opioid-Sparing Effect of Dronabinol When Coadministered With Opioid Analgesics to Chronic Pain Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daisy Pharma Opioid Venture, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daisy Pharma Opioid Venture, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a 12-week, open-label trial that is designed to evaluate the&#xD;
      Opioid-Sparing effect of Dronabinol at ranging doses when coadministered with the opioid&#xD;
      analgesics that are currently being prescribed to patients for their chronic pain condition.&#xD;
      The purpose of this trial will be to assess the effectiveness of Dronabinol when combined&#xD;
      with opioid analgesics to relieve pain at lower opioid doses and to evaluate any reduction of&#xD;
      opioid-related side effects. Participants will take the study-drug, Dronabinol, along with&#xD;
      their regular prescribed opioids and the results will be evaluated and analyzed according to&#xD;
      defined endpoints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Week one of the study is a Baseline Period during which time, baseline data related to opioid&#xD;
      dose and frequency, mood, sleep, bowel movements, and pain intensity will be collected.&#xD;
      Participants will receive no Dronabinol during week one and will continue to take their&#xD;
      stabilized dose of regular prescribed opioids, both baseline and rescue.&#xD;
&#xD;
      Weeks two through four is the Titration Period, during which time study participants will&#xD;
      titrate the Dronabinol dose up to a daily dose of 20 mg of Dronabinol per day, according to a&#xD;
      prearranged titration table. Participants will continue to take their stabilized dose of&#xD;
      regular prescribed opioids, both baseline and rescue. Participants will be encouraged to&#xD;
      maintain the 20mg daily total dose of Dronabinol. Participants may also reduce their dose of&#xD;
      Dronabinol at any time (if they experience severe adverse effects) to a minimum daily dose of&#xD;
      Dronabinol of 10mg per day. Participants who cannot tolerate at least a minimum daily dose of&#xD;
      10mg of Dronabinol per day will be discontinued from the study.&#xD;
&#xD;
      Weeks five through twelve is the Opioid-Sparing Period, during which time participants will&#xD;
      be encouraged to maintain the stabilized dose of Dronabinol that they &quot;found&quot; during the&#xD;
      Study-Drug Dose Finding Period. Study Participants will continue to take their regular&#xD;
      prescribed opioids, but will be encouraged to reduce their opioid dose and/or opioid dose&#xD;
      frequency at any time during the remainder of the study should they experience a reduction in&#xD;
      pain and/or an improvement in opioid-related side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity Scale (0-10)</measure>
    <time_frame>Daily (Days 1-82)</time_frame>
    <description>To measure the change in pain intensity from baseline using the Opioid Sparing Diary Toolkit. The measurement of the pain intensity will be derived from the Brief Pain Inventory (Short-Form) item #3. &quot;Please rate your pain by marking the box beside the number that best describes your pain at its worst in the last 24 hours.&quot; The score is reported as a value between 0 and 10, with 0 indicative of no pain, and 10 indicative of &quot;pain as bad as you can imagine&quot;. The score will be considered a continuous level of measurement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-Reported Opioid Use (Opioid Dose)</measure>
    <time_frame>Daily (Days 1-82)</time_frame>
    <description>To measure the change in opioid dose from baseline using the Opioid Sparing Diary Toolkit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-Reported Opioid Use Frequency (Opioid Dose Frequency)</measure>
    <time_frame>Daily (Days 1-82)</time_frame>
    <description>To measure the change in opioid use frequency from baseline using the Opioid Sparing Diary Toolkit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI)</measure>
    <time_frame>Study Visits 1-5 (Days 1, 14, 28, 56, 82)</time_frame>
    <description>To evaluate and measure any changes in pain history, intensity, location, relief, and life interference indicators from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital and Anxiety Depression Scale (HADS)</measure>
    <time_frame>Study Visits 1-5 (Days 1, 14, 28, 56, 82)</time_frame>
    <description>To measure the change in depression and generalized anxiety from baseline. The HADS measures levels of anxiety and depression that a patient is experiencing. The HADS is a fourteen item scale. Seven of the items relate to a factor that measures anxiety and seven relate to a factor that measures depression. The seven items for each factor are summed into a total score and range from 0 to 21, with higher scores indicative of greater anxiety/depression. The scores will be analyzed as continuous level variables and one-sided paired-samples t-tests will be used to compare mean scores for anxiety and depression for all subjects between Week 1 (baseline) and Week 12 (EOS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effect Checklist 29-item</measure>
    <time_frame>Study Visits 1-5 (Days 1, 14, 28, 56, 82)</time_frame>
    <description>To evaluate the presence or absence of side effects associated with the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAND Health Survey 36-item</measure>
    <time_frame>Study Visits 1-5 (Days 1, 14, 28, 56, 82)</time_frame>
    <description>To measure the change in overall quality of life from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MOS Sleep Scale</measure>
    <time_frame>Study Visits 1-5 (Days 1, 14, 28, 56, 82)</time_frame>
    <description>To measure the change in quality of sleep from baseline. The MOS Sleep Scale Self Report includes 12 items which measure 7 individual continuous-level factors relating to sleep quality: (a) sleep disturbances, (b) snoring, (c) sleep short of breath or headache, (d) sleep adequacy, (e) sleep somnolence, (f) sleep problems index I, and (g) sleep problems index II. Each of the seven factors is scored via a two-step process such that higher resulting scores are indicative of greater sleep problems. All 7 scores are measured at the continuous level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication (TSQM)</measure>
    <time_frame>Study Visits 1-5 (Days 1, 14, 28, 56, 82)</time_frame>
    <description>To measure the change in satisfaction with medication from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel Function Inventory-Revised (BFI-R)</measure>
    <time_frame>Study Visits 1-5 (Days 1, 14, 28, 56, 82)</time_frame>
    <description>To measure the change in Opioid-Induced Constipation from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Current Opioid Misuse Measure (COMM)</measure>
    <time_frame>Study Visits 1-5 (Days 1, 14, 28, 56, 82)</time_frame>
    <description>To measure the change in Possible Opioid Misuse from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical Opioid Side Effect (NOSE) Assessment</measure>
    <time_frame>Study Visits 1-5 (Days 1, 14, 28, 56, 82)</time_frame>
    <description>To measure the change in Opioid Side Effect Severity from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OSD: Mood Scale Self Report (0-10)</measure>
    <time_frame>Daily (Days 1-82)</time_frame>
    <description>To measure the change in Mood from baseline. The Mood Scale is a 10 item Likert-scaled instrument with each of the 10 items scored from 1 = absolutely miserable to 10 = absolutely happy. The scores for each of the 10 items will be summed into a mood total score. The mood total score can range from 10 to 100, with higher scores indicative of happier states. The mood total score is a continuous level of measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OSD: Sleep Scale Self Report (0-10)</measure>
    <time_frame>Daily (Days 1-82)</time_frame>
    <description>To measure the change in Quality of Sleep from baseline. The Sleep Scale is a 10 item Likert-scaled instrument with each of the 10 items scored from 1 = worst imaginable to 10 = best . The scores for each of the 10 items will be summed into a sleep total score. The sleep total score can range from 10 to 100, with higher scores indicative of better quality sleep. The sleep total score is a continuous level of measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OSD: Bowel Movement 24-Hour Self Report Survey</measure>
    <time_frame>Daily (Days 1-82)</time_frame>
    <description>To measure the change in number of Bowel Movements from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FITBIT: Sleep Tracker</measure>
    <time_frame>Daily (Days 1-82)</time_frame>
    <description>To measure the change in quantity and quality of sleep from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FITBIT: Distance Tracker</measure>
    <time_frame>Daily (Days 1-82)</time_frame>
    <description>To measure the change in average weekly distance traveled from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FITBIT: Caloric Expenditure Tracker</measure>
    <time_frame>Daily (Days 1-82)</time_frame>
    <description>To measure the change in average weekly calories expended from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Billing Claims Data for each participant</measure>
    <time_frame>Study Visits 1 &amp; 5 (Days 1 &amp; 82)</time_frame>
    <description>To evaluate the change in Health Care Expenditures Related To Chronic Pain from baseline (average monthly expenditures before study)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Baseline Opioid</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One of Seven existing Baseline Opioid subgroups (Hydrocodone, Oxycodone, Morphine, Hydromorphone, Buprenorphine, Tramadol) coadministered with intervention drug, Dronabinol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol</intervention_name>
    <description>Dronabinol coadministered with patient's existing Baseline Opioid.</description>
    <arm_group_label>Baseline Opioid</arm_group_label>
    <other_name>Marinol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to read, speak, and understand English;&#xD;
&#xD;
          2. Provision of signed and dated informed consent form;&#xD;
&#xD;
          3. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study;&#xD;
&#xD;
          4. Male, Female, or Transgender aged &gt; 18;&#xD;
&#xD;
          5. In fair and stable general health as evidenced by medical history and physical&#xD;
             examination, and confirmed by prescriber;&#xD;
&#xD;
          6. Participants who have been diagnosed with a pain condition that has not adequately&#xD;
             responded to other treatments, in the judgement of the provider;&#xD;
&#xD;
          7. Participants who are currently taking a stabilized dose of opioid analgesics, and who&#xD;
             have been taking opioid analgesics for at least 3-months, and who report a score of &gt;&#xD;
             3 on the Brief Pain Inventory 0-10 severity index.;&#xD;
&#xD;
          8. Ability to take medications as prescribed and willingness to adhere to the study-drug&#xD;
             regimen;&#xD;
&#xD;
          9. For females of reproductive potential: use of highly effective contraception for at&#xD;
             least 1 month prior to enrollment and agreement to use such a method during study&#xD;
             participation;&#xD;
&#xD;
         10. Agreement to abstain from the use of cannabis or other cannabinoid compounds, other&#xD;
             than the study-drug Dronabinol, throughout study duration;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current substance abuse by self-report;&#xD;
&#xD;
          2. Current use of cannabis or other cannabinoid compounds;&#xD;
&#xD;
          3. Significant baseline nausea, vomiting, sedation, or other symptoms reported by&#xD;
             physician and or patient that may compromise the collection of study-related data;&#xD;
&#xD;
          4. A history of seizures, head trauma, and or mental illness ;&#xD;
&#xD;
          5. Pregnancy or lactation;&#xD;
&#xD;
          6. Known allergic reactions to components of Dronabinol;&#xD;
&#xD;
          7. Taking any of the following drugs:&#xD;
&#xD;
        Strong CYP2C9 Inhibitor (e.g., amiodarone, fluconazole) Strong CYP3A4 Inhibitor (e.g.,&#xD;
        ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin) Potent CYP2C9 or&#xD;
        CYP3A4 inducers (e.g., rifampicin) Drugs that are highly protein-bound (e.g., warfarin,&#xD;
        cyclosporine, amphotericin B)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kendric B Speagle, BA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daisy Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kendric B Speagle, BA</last_name>
    <phone>4803559000</phone>
    <email>kendric@daisyrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Daisy Research, Inc.</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KENDRIC B SPEAGLE, BA</last_name>
      <phone>480-355-9000</phone>
      <email>kendric@daisyrx.com</email>
    </contact>
    <investigator>
      <last_name>Kendric B Speagle, BA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>December 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2018</study_first_posted>
  <last_update_submitted>December 4, 2018</last_update_submitted>
  <last_update_submitted_qc>December 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03766269
org study id: 140635
nct id: NCT03766269
lead sponsor: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
is us export: No
This study will be a 12-week, open-label trial that is designed to evaluate the
      Opioid-Sparing effect of Dronabinol at ranging doses when coadministered with the opioid
      analgesics that are currently being prescribed to patients for their chronic pain condition.
      The purpose of this trial will be to assess the effectiveness of Dronabinol when combined
      with opioid analgesics to relieve pain at lower opioid doses and to evaluate any reduction of
      opioid-related side effects. Participants will take the study-drug, Dronabinol, along with
      their regular prescribed opioids and the results will be evaluated and analyzed according to
      defined endpoints.
Week one of the study is a Baseline Period during which time, baseline data related to opioid
      dose and frequency, mood, sleep, bowel movements, and pain intensity will be collected.
      Participants will receive no Dronabinol during week one and will continue to take their
      stabilized dose of regular prescribed opioids, both baseline and rescue.

      Weeks two through four is the Titration Period, during which time study participants will
      titrate the Dronabinol dose up to a daily dose of 20 mg of Dronabinol per day, according to a
      prearranged titration table. Participants will continue to take their stabilized dose of
      regular prescribed opioids, both baseline and rescue. Participants will be encouraged to
      maintain the 20mg daily total dose of Dronabinol. Participants may also reduce their dose of
      Dronabinol at any time (if they experience severe adverse effects) to a minimum daily dose of
      Dronabinol of 10mg per day. Participants who cannot tolerate at least a minimum daily dose of
      10mg of Dronabinol per day will be discontinued from the study.

      Weeks five through twelve is the Opioid-Sparing Period, during which time participants will
      be encouraged to maintain the stabilized dose of Dronabinol that they "found" during the
      Study-Drug Dose Finding Period. Study Participants will continue to take their regular
      prescribed opioids, but will be encouraged to reduce their opioid dose and/or opioid dose
      frequency at any time during the remainder of the study should they experience a reduction in
      pain and/or an improvement in opioid-related side effects.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Pain Intensity Scale (0-10)
time frame: Daily (Days 1-82)
description: To measure the change in pain intensity from baseline using the Opioid Sparing Diary Toolkit. The measurement of the pain intensity will be derived from the Brief Pain Inventory (Short-Form) item #3. "Please rate your pain by marking the box beside the number that best describes your pain at its worst in the last 24 hours." The score is reported as a value between 0 and 10, with 0 indicative of no pain, and 10 indicative of "pain as bad as you can imagine". The score will be considered a continuous level of measurement.
measure: Self-Reported Opioid Use (Opioid Dose)
time frame: Daily (Days 1-82)
description: To measure the change in opioid dose from baseline using the Opioid Sparing Diary Toolkit
measure: Self-Reported Opioid Use Frequency (Opioid Dose Frequency)
time frame: Daily (Days 1-82)
description: To measure the change in opioid use frequency from baseline using the Opioid Sparing Diary Toolkit
measure: Brief Pain Inventory (BPI)
time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)
description: To evaluate and measure any changes in pain history, intensity, location, relief, and life interference indicators from baseline
measure: Hospital and Anxiety Depression Scale (HADS)
time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)
description: To measure the change in depression and generalized anxiety from baseline. The HADS measures levels of anxiety and depression that a patient is experiencing. The HADS is a fourteen item scale. Seven of the items relate to a factor that measures anxiety and seven relate to a factor that measures depression. The seven items for each factor are summed into a total score and range from 0 to 21, with higher scores indicative of greater anxiety/depression. The scores will be analyzed as continuous level variables and one-sided paired-samples t-tests will be used to compare mean scores for anxiety and depression for all subjects between Week 1 (baseline) and Week 12 (EOS).
measure: Side Effect Checklist 29-item
time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)
description: To evaluate the presence or absence of side effects associated with the intervention
measure: RAND Health Survey 36-item
time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)
description: To measure the change in overall quality of life from baseline
measure: MOS Sleep Scale
time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)
description: To measure the change in quality of sleep from baseline. The MOS Sleep Scale Self Report includes 12 items which measure 7 individual continuous-level factors relating to sleep quality: (a) sleep disturbances, (b) snoring, (c) sleep short of breath or headache, (d) sleep adequacy, (e) sleep somnolence, (f) sleep problems index I, and (g) sleep problems index II. Each of the seven factors is scored via a two-step process such that higher resulting scores are indicative of greater sleep problems. All 7 scores are measured at the continuous level.
measure: Treatment Satisfaction Questionnaire for Medication (TSQM)
time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)
description: To measure the change in satisfaction with medication from baseline
measure: Bowel Function Inventory-Revised (BFI-R)
time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)
description: To measure the change in Opioid-Induced Constipation from baseline
measure: Current Opioid Misuse Measure (COMM)
time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)
description: To measure the change in Possible Opioid Misuse from baseline
measure: Numerical Opioid Side Effect (NOSE) Assessment
time frame: Study Visits 1-5 (Days 1, 14, 28, 56, 82)
description: To measure the change in Opioid Side Effect Severity from baseline
measure: OSD: Mood Scale Self Report (0-10)
time frame: Daily (Days 1-82)
description: To measure the change in Mood from baseline. The Mood Scale is a 10 item Likert-scaled instrument with each of the 10 items scored from 1 = absolutely miserable to 10 = absolutely happy. The scores for each of the 10 items will be summed into a mood total score. The mood total score can range from 10 to 100, with higher scores indicative of happier states. The mood total score is a continuous level of measurement.
measure: OSD: Sleep Scale Self Report (0-10)
time frame: Daily (Days 1-82)
description: To measure the change in Quality of Sleep from baseline. The Sleep Scale is a 10 item Likert-scaled instrument with each of the 10 items scored from 1 = worst imaginable to 10 = best . The scores for each of the 10 items will be summed into a sleep total score. The sleep total score can range from 10 to 100, with higher scores indicative of better quality sleep. The sleep total score is a continuous level of measurement.
measure: OSD: Bowel Movement 24-Hour Self Report Survey
time frame: Daily (Days 1-82)
description: To measure the change in number of Bowel Movements from baseline
measure: FITBIT: Sleep Tracker
time frame: Daily (Days 1-82)
description: To measure the change in quantity and quality of sleep from baseline
measure: FITBIT: Distance Tracker
time frame: Daily (Days 1-82)
description: To measure the change in average weekly distance traveled from baseline
measure: FITBIT: Caloric Expenditure Tracker
time frame: Daily (Days 1-82)
description: To measure the change in average weekly calories expended from baseline
measure: Medical Billing Claims Data for each participant
time frame: Study Visits 1 & 5 (Days 1 & 82)
description: To evaluate the change in Health Care Expenditures Related To Chronic Pain from baseline (average monthly expenditures before study)
arm group label: Baseline Opioid
arm group type: Other
description: One of Seven existing Baseline Opioid subgroups (Hydrocodone, Oxycodone, Morphine, Hydromorphone, Buprenorphine, Tramadol) coadministered with intervention drug, Dronabinol.
intervention type: Drug
intervention name: Dronabinol
description: Dronabinol coadministered with patient's existing Baseline Opioid.
arm group label: Baseline Opioid
other name: Marinol
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: Accepts Healthy Volunteers
last name: Kendric B Speagle, BA
role: Principal Investigator
affiliation: Daisy Research
last name: Kendric B Speagle, BA
phone: 4803559000
email: kendric@daisyrx.com
facility: 
status: Recruiting
contact: 
investigator: 
country: United States
responsible party type: Sponsor
mesh term: Chronic Pain
mesh term: Dronabinol
sharing ipd: Undecided